What is the Difference Between Dihydropyridine and Nondihydropyridine Calcium Channel Blockers?
🆚 Go to Comparative Table 🆚Dihydropyridine and nondihydropyridine calcium channel blockers are two subclasses of calcium channel blockers (CCBs), which are medications that block calcium channels in the muscle cells of the heart and blood vessels, promoting blood vessel dilation and reducing blood pressure. The main differences between these two subclasses are:
- Selectivity: Dihydropyridines are more vascular-selective, meaning they primarily act on vascular smooth muscles, while nondihydropyridines are more myocardial-selective, meaning they have a greater effect on the heart muscle.
- Pharmacological Effects: Dihydropyridine CCBs tend to be more potent vasodilators than nondihydropyridine CCBs, which have more marked negative inotropic effects. Both subclasses have a similar capacity to lower blood pressure, but nondihydropyridines may offer potential advantages in the management of patients with chronic kidney disease.
- Examples: Dihydropyridines include medications like nifedipine and amlodipine, while nondihydropyridines include verapamil and diltiazem.
Both dihydropyridine and nondihydropyridine CCBs are used to treat conditions such as hypertension and angina pectoris, but their specific uses and effects may vary depending on the individual patient's needs and the determination of the treating physician.
Comparative Table: Dihydropyridine vs Nondihydropyridine Calcium Channel Blockers
Dihydropyridine and nondihydropyridine calcium channel blockers are two subclasses of calcium channel blockers (CCBs) that differ in their selectivity and effects on blood vessels and heart muscles. Here is a table comparing the differences between the two:
Property | Dihydropyridine Calcium Channel Blockers | Nondihydropyridine Calcium Channel Blockers |
---|---|---|
Selectivity | Selective for L-type calcium channels in vascular smooth muscle | Non-selective, targeting both vascular and cardiac calcium channels |
Vasodilation | More potent vasodilators | Less potent vasodilators, but have significant negative inotropic effects |
Heart Conduction Slowing Effect | Lack a conduction-slowing effect, which makes them safe to combine with beta-blockers | More likely to have a conduction-slowing effect |
Common Subtypes | Nifedipine, Amlodipine | Verapamil, Diltiazem |
Treatment Applications | Predominantly peripheral vasodilatory actions | Significant negative inotropic effects and more systemic use, including in chronic kidney disease |
In summary, dihydropyridine CCBs primarily target calcium channels on the smooth muscles and have a predominantly peripheral vasodilatory action, while nondihydropyridine CCBs target calcium channels in the heart and possess significant negative inotropic effects.
- Beta Blocker vs Calcium Channel Blocker
- Nifedipine vs Amlodipine
- Amlodipine vs Lercanidipine
- Depolarizing vs Nondepolarizing Neuromuscular Blockers
- Amlodipine vs Amlodipine Besylate
- Calcium vs Calcium Citrate
- Catecholamines vs Noncatecholamines
- Telmisartan vs Amlodipine
- Dicalcium Phosphate vs Monocalcium Phosphate
- Calcium Carbonate vs Calcium Citrate
- Ace Inhibitors vs Angiotensin Receptor Blockers
- Alpha vs Beta Blockers
- Isosorbide Mononitrate vs Isosorbide Dinitrate
- Calcium vs Magnesium
- Calcium Chloride vs Calcium Chloride Dihydrate
- Citracal vs Caltrate
- Troponin vs Calmodulin
- Hydrochloride vs Dihydrochloride
- Calcium Oxalate Monohydrate vs Calcium Oxalate Dihydrate